Thursday, July 23, 2020 1:20:22 PM
From the MD&A on page 8:
As well as the cash resources the Company had, at June 30, 2020, invested in $75,000 in a convertible debenture in Immunoprecise Antibodies Ltd, bearing interest at 10%, maturing on May 15, 2022 and convertible into common shares at a price of $0.85 per share. This resulted in short term cash and term deposits of $457,426, compared to an equivalent amount of $305,829 at December 31, 2019.
News release:
Spectra Products Inc. Reports Second Quarter 2020 Results For Immediate Release – July 23, 2020 Toronto, Ontario – Spectra Products Inc. (SSA: TSX VENTURE) reports the release of its financial results for the six months ended June 30, 2020. Revenues for the six-month period ending June 30, 2020 were $841,277 compared to $1,163,817 for the same period in 2019. Revenues for the second quarter ending June 30, 2020 were $305,351 compared to $668,310 for the same period in 2019. In the six-month period ended June 30, 2020, a net profit before income taxes of $251,375 was earned compared to a net profit before income taxes of $298,949 for the six-month period ended June 30, 2019. In the second quarter ended June 30, 2020, a net profit before income taxes of $74,862 was earned compared to a net profit before income taxes of $192,662 for the second quarter ended June 30, 2019. As a result of the COVID-19 virus, the slow-down in the various market segments reduced the Company’s revenue levels in the second quarter of 2020, however the Company was still able to remain profitable. The Company has strong cash reserves and is well positioned to maintain operations, albeit at reduced levels of revenue and profitability, until market levels return to normal. Spectra Products Inc. is the Toronto-based North American designer, manufacturer and distributor of wheel end safety products to the transportation industry. These products include Brake SafeÒ, Brake InspectorÒ, Zafety Lug LockÒ, Hub Alert™ and the Anti-Seize Cotter Pin™ as well as the Termin-8RÒ line of anti-corrosion and extreme pressure lubricants. Except for the historical information contained herein, this news release contains forward looking statements that involve risks and uncertainties, including the impact of competitive products and pricing and general economic conditions as they affect the Corporation’s customers. Actual results and developments may therefore differ materially from those described in this release. On behalf of the Board of Directors, Andrew Malion, President, Spectra Products Inc. Investor Relations: 1-800-308-5255 E-Mail: info@spectrainc.ca Website: www.spectrainc.ca
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM